Boardroom Alpha
Start trial
10-K primary document
CORT · Annual Report (Form 10-K) · Filed February 24, 2026

Corcept Therapeutics Inc — 10-K exhibit

cort2025ex1026xfirstamendm.htm
Corcept Therapeutics Inc on Boardroom Alpha
Document
Exhibit 10.26

FIRST AMENDMENT TO THE STATEMENT OF WORK NO. 1
This First Amendment to the Statement of Work No. 1 (this “Amendment”) made as of October 10, 2025 (the “Amendment Effective Date”) by and between CORCEPT THERAPEUTICS INCORPORATED, a Delaware corporation (“Corcept”), and CURANT HEALTH GEORGIA, LLC, a Georgia limited liability company (“Curant,” and together with all of Curant’s licensed pharmacy locations listed in the Agreement, “Pharmacy”) hereby amends the original Statement of Work No. 1 (the “SOW”) executed by the Parties and dated as of June 13, 2025, pursuant to that certain Master Pharmacy Services Agreement between the Parties dated as of June 13, 2025 (the “Agreement”).
WHEREAS, the Parties have agreed to amend the SOW to include Corcept’s product relacorilant, which is anticipated to be approved and available within the term of the SOW;
NOW, THEREFORE, the Parties agree as follows:
1.Definitions: The “Products” definition in Section 3 of the SOW is amended and restated in its entirety as follows:

“Products” means KORLYM® (mifepristone), NDC Number: 76346-073-01 and 76346-073-02; Corcept’s authorized generic mifepristone, NDC Number: 76346-654-03 and Corcept’s relacorilant for endocrinology, NDC Number: TBD.

2.Governing Terms: All other terms and conditions of the Agreement and the SOW that are not expressly amended or modified by this Amendment shall remain in full force and effect.

IN WITNESS WHEREOF, an authorized representative of each undersigned Party has signed this Amendment, intending to be bound hereby.

CORCEPT THERAPEUTICS INC.
CURANT HEALTH GEORGIA, LLC
By:
/s/ J.D. Lyon
By
/s/ Patrick Dunham
Name:
J.D. Lyon
Name:
Patrick Dunham
Title:
Chief Pharmacy Officer
Title:
CEO
Date
10/23/2025
Date
10/21/2025
48503501.2

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer